Perspectives of proteomics investigations of neuroblastoma chemoresistance

Annamaria D'Alessandro, Valeria Marzano, Simona D'Aguanno, Luisa Pieroni, Sergio Bernardini, Giorgio Federici, Andrea Urbani

Research output: Chapter in Book/Report/Conference proceedingChapter


Neuroblastoma, the third most common paediatric solid tumors afterleukaemiae and brain neoplasiae, with an incidence of approximately 1.3child out of 100.000, is responsible of 15% of all childhood cancer death.The acquisition of multidrug resistance upon treatment with anticancerdrugs is a common feature of highly malignant Neuroblastoma. Theidentification of marker proteins involved in chemo-resistance mightsignificantly help in the prognosis of this neoplasia by individualising thedrug treatment .Proteomics investigation might represent a powerful holistic scientificapproach in order to possibly characterised the molecular hallmarks ofNeuroblastoma chemoresistance. Combining high-resolution proteinseparations with mass spectrometry protein identification, proteomics allowsto explore the molecular mechanisms of cancer chemoresistance in a datadriven experimental design, therefore enabling the construction of novelhypothesis not necessarily linked to a define researcher theory.In the following we review the current state of the art in the proteomicsinvestigations devoted to the characterisation of Neuroblastoma drugresistance.

Original languageEnglish
Title of host publicationNeuroblastoma Research Trends
PublisherNova Science Publishers, Inc.
Number of pages22
ISBN (Print)9781604567908
Publication statusPublished - Apr 2008


  • Cancer
  • Chemoresistance
  • Neuroblastoma
  • Pediatry
  • Proteomics

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Perspectives of proteomics investigations of neuroblastoma chemoresistance'. Together they form a unique fingerprint.

Cite this